# Vascular Response of Orsiro vs. Xience Drug-Eluting Stents for Treating Coronary Bifurcation Lesions

Study · id `cardio:ct-nct05200637` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05200637](<https://clinicaltrials.gov/study/NCT05200637>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05200637

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

## Technical summary

Registry record NCT05200637. Randomized; no masking; primary purpose treatment. Start 2022-02-01 (anticipated); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT05200637, source copy `cardio:ctgov-nct05200637-2022-01-21`, retrieved 2026-10-26)
- Planned start: 2022-02-01 (anticipated) (ClinicalTrials.gov record NCT05200637, source copy `cardio:ctgov-nct05200637-2022-01-21`, retrieved 2026-10-26)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT05200637, source copy `cardio:ctgov-nct05200637-2022-01-21`, retrieved 2026-10-26)
- Completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT05200637, source copy `cardio:ctgov-nct05200637-2022-01-21`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT05200637, source copy `cardio:ctgov-nct05200637-2022-01-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05200637-2022-01-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Vascular Response of Orsiro vs. Xience Drug-Eluting Stents for Treating Coronary Bifurcation Lesions
- Condition: Coronary Artery Disease
- Intervention (Device): Orsiro stent
- Intervention (Device): Xience stent
- Intervention (Device): Any drug-eluting stent
- Lead sponsor: Chang Gung Memorial Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Chang Gung Memorial Hospital (`cardio:org-chang-gung-memorial-hospital`)

## Provenance

Content hash: 7e32be3d3ca0c21ed1573680fca0f3f1849966e97d5752ee207cc44160f18e1d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
